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Objective: To preliminarily investigate the possible role of prostaglandin D2 (PGD2) in
malaria infections.
Methods: Blood and urinary samples (n = 120 each) were collected from Thai patients
with Plasmodium falciparum (P. falciparum) with moderate (n = 26) and high (n = 4)
parasitemia, patients with Plasmodium vivax (P. vivax) (n = 30), patients with fever
associated with other infections (n = 30), and healthy subjects (n = 30). PGD2 concen-
trations in plasma and urinary samples of healthy subjects, patients with fever associated
with other infections and patients with malaria were determined using Prostaglandin D2-
MOX express EIA kit (Cayman Chemical, USA).
Results: The possible association between PGD2 and malaria infections is clearly
demonstrated with PGD2 concentration in urine. The urinary PGD2 concentrations were
relatively high (about 5-fold) in patients with P. falciparum with moderate parasitemia
and P. vivax infections compared with other groups. Furthermore, the concentration in
patients with P. falciparum with moderate parasitemia and P. vivax infection were
signiﬁcantly higher than that in healthy subjects and patients with fever associated with
other infections.
Conclusions: Urinary PGD2 concentrations may offer a more dependable and useful tool
for predicting malaria severity. Conﬁrmation is this preliminary ﬁnding is required with a
larger sample size.1. Introduction
Globally, an estimated 3.2 billion people in 97 countries and
territories are at risk of being infected with malaria and devel-
oping disease and 1.2 billion are at high risk. According to the
latest estimates, 198 million cases of malaria occurred globally
in 2013 and the disease led to 584000 deaths, representing a
decrease in malaria case incidence and mortality rates of 30%
and 47% since 2 000, respectively [1]. Among all human malariaspecies, Plasmodium falciparum (P. falciparum) is the most
severe form with regard to morbidity and mortality. Several
factors associated with pathogenesis and severity of severe
P. falciparum have been reported, but major factors involve
the production of cytokines (IL-4, IL-12) and tumor necrosis
factor (TNF) [2,3]. Recently, the hypothetical role of
hemeoxygenase-1 (HO-1) enzyme in pathogenesis of severe
and cerebral malaria has been proposed as one of the important
factors that may be linked with susceptibility and severity of
malaria infections [4]. HO-1 is the enzyme involved in heme
breakdown process to release iron, carbon monoxide, and bili-
verdin/bilirubin. This process therefore inﬂuences iron supply
that support the growth of P. falciparum [5]. The expression of
HO-1 is induced by several substances particularly prosta-
glandin D2 (PGD2). PGD2 is the most important prostanoid
produced in the brain that regulates sleep and pain responses [5].
The production of PGD2 is induced through transcriptionalticle under the CC BY-NC-ND license (http://
Pimwan Thongdee et al./Asian Paciﬁc Journal of Tropical Medicine 2016; 9(9): 856–859 857activation of cyclooxygenase-2, as well as heme degradation [6].
It is thought that intra-erythrocytic P. falciparum parasites
release PfPGD2 which may inﬂuence heme catabolism in the
host cells near the parasite sequestration sites. The sequestered
parasitized erythrocytes then generate hemodynamic stress,
which in turn, increase the production of PfPGD2 through in-
duction of the expression of lipocalin-type prostaglandin D2
synthase in vascular endothelial cells as reported in the case of
ﬂuid shear stress [7]. The aim of the present study was to
preliminarily investigate the possible role of PGD2 in malaria
infections through measuring its concentrations in blood and
urinary samples collected from Thai patients with
P. falciparum, Plasmodium vivax (P. vivax), patients with
fever, and healthy subjects of both genders and all age groups.
2. Material and methods
2.1. Study areas and sample collection
The study was conducted at Mae Sot General Hospital, Mae
Sot, Tak Province, Thailand. Approval of the study protocol was
obtained from the Ethics Committees of Ministry of Public
Health of Thailand. A total of 120 blood and urine samples were
collected (before treatment) from Thai patients with P. vivax
(n = 30), patients with P. falciparum [n = 26 and 4 for moderate
(1000–50000 asexual parasite/mL), and high parasitemia
(>50000 asexual parasite/mL), respectively)], patients with fever
associated with other infections (n = 30), and healthy subjects
(n = 30). Written informed consents for study participation were
obtained from all participants [89 males and 31 females, aged
(12–90) years] before study.
Blood sample (3 mL) was collected from each participant and
serum and plasma (with EDTA anticoagulant and 10 mM
indomethacin) samples were prepared through centrifugation at
1 500 × g for 15 min (4 C). Random mid-stream urine sample
(2 mL) was collected and immediately stored at −80 C without
pretreatment with any preservative.
2.2. Sample extraction
Plasma sample was diluted with cold acetone at the ratio of
1:1 (v:v) and incubated on ice for 5 min. The precipitated
protein was removed through centrifugation at 8000 × g for
10 min and stored at −20 C until analysis. Before analysis,
the sample was evaporated to dryness using Centri-vap cold
trap and the dried sample was resuspended in 100 mL of EIA
buffer. Methoximation was performed using Prostaglandin
D2-MOX express EIA kit according to the procedure provided
by the manufacturer. Concentrations of bilirubin (direct and
total) in serum samples were determined immediately after
sample collection by diazonium salt 3,5-dichlor-
ophenyldiazonium tetraﬂuoroborate (DPD) method. Creati-
nine concentrations in urine samples were determined using
Jaffe's reaction method.
2.3. Determination of PGD2 concentrations
PGD2 concentrations in plasma and urine samples were
determined using Prostaglandin D2-MOX express EIA kit
(Cayman Chemical, USA). Brieﬂy, 50 mL of plasma (1:10
dilution) or urine (1:5 dilution) was added in a 96-well platecoated with goat anti-rabbit IgG antibodies. The tracer (50 mL)
and the PGD2 speciﬁc antibody (50 mL) were added to each
well. The plate was incubated overnight at 4 C and washed ﬁve
times with 10 mM phosphate buffer (pH 7.4) containing Tween
20 (0.05%) pH 7.4. Two-hundred mL of Ellman's reagent
[69 mM acetylthiocholine and 54 mM 5,50-dithio-bis (2-
nitrobenzoic acid) in 10 mM phosphate buffer pH 7.4] was
added to each well and the plate was incubated in a dark room at
25 C for (60–90) min. Concentration of the reaction product
(yellow solution) was spectroscopically measured using a
microplate reader at the wavelength of 410 nm. A standard curve
was developed using computer spreadsheet of Cayman Chemi-
cal Company and concentrations of PGD2 in plasma and urine
samples relative to those standards were determined.2.4. Statistical analysis
Difference in PGD2 concentrations in samples of all groups
were determined using Kruskal–Wallis test followed by Mann–
Whitney U test for data not conforming to normal distribution.
Statistical signiﬁcance level was set at a = 0.05 for all tests.3. Results
3.1. Association between plasma PGD2 concentrations
and malaria infections
Median (range) values of plasma PGD2 concentrations in
samples collected from patients with P. vivax, patients with
P. falciparum (moderate and high parasitemia), patients with
fever associated with other infections, and healthy subjects are
summarized in Table 1. The concentration was highest (about
3-fold) in patients with fever associated with other infections
compared with other groups. The concentration in
P. falciparum infection with moderate parasitemia was
signiﬁcantly higher than healthy subjects (P < 0.0001), but
signiﬁcantly lower than P. vivax infection (P < 0.0001) and
patients with fever associated with other infections
(P < 0.0001). For P. vivax infection, the concentration was
signiﬁcantly higher than patients with P. falciparum with
moderate parasitemia (P < 0.0001) and healthy subjects
(P < 0.0001), but signiﬁcantly lower than patients with fever
associated with other infections (P < 0.05).3.2. Association between serum bilirubin concentrations
and malaria infections
Median (range) values of serum concentrations of bilirubin
(direct and total) in samples collected from all groups are
summarized in Table 1. The concentrations in patients with
P. falciparum with moderate parasitemia and P. vivax infections
were signiﬁcantly higher than healthy subjects (P < 0.05 and
P < 0.05, respectively). The increased bilirubin level did not
interfere the measurement of serum PGD2 level.
The median (range) direct bilirubin concentrations in patients
with P. falciparum with moderate parasitemia and P. vivax in-
fections were signiﬁcantly higher than healthy subjects
(P < 0.05 and P < 0.05, respectively). In addition, the con-
centration in patients with fever associated with other infections
was signiﬁcantly higher than healthy subjects (P < 0.05).
Table 1
Median (range) plasma concentrations of PGD2, serum total bilirubin concentration, serum direct bilirubin concentration, urinary PGD2 concentration

















Control Group 30 16 (6–30)a,b,c 0.50 (0.26–1.10)e,f 0.27 (0.02–0.51)d,e,f 26 (7–41)d,f 106.16 (20.80–267.73)e,f
Group A 30 60 (11–525)b,f,g 0.57 (0.12–29.26) 0.33 (0.09–16.25)h 23 (7–120)e,f 75.35 (26.90–303.60)e,f,h
Group B 26 22 (13–75)a,c,g 1.11 (0.38–2.78)f,h 0.49 (0.17–1.03)d,h 120 (29–325)d,h 188.80 (61.90–378.30)d,h
Group C 4 28 (16–38) 1.24 (0.74–1.74) 0.66 (0.30–1.03) 56 (49–260) 203.90 (151.50–274.60)
Group D 30 34 (22–130)b,d,g 0.91 (0.33–2.74)e,h 0.43 (0.18–1.70)h 139 (23–1123)d,h 183.75 (47.80–349.20)d,h
Control Group: Healthy subjects. Group A: Patients with fever associated with other infections; Group B: P. falciparum with moderate parasitemia;
Group C: P. falciparum with high parasitemia; Group D: P. vivax.
a P < 0.0001 compared with Group A. b P < 0.0001 compared with Group B. c P < 0.0001 compared with Group D. d P < 0.05 compared with
Group A. e P < 0.05 compared with Group B. f P < 0.05 compared with Group D. g P < 0.0001 compared with Control Group. h P < 0.05 compared
with Control Group.
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and malaria infections
Median (range) values of urinary PGD2 concentrations in
plasma samples collected from all groups are summarized in
Table 1. The median urinary PGD2 concentrations were rela-
tively high (about 5-fold) in patients with P. falciparum with
moderate parasitemia and P. vivax infections compared with
other groups. The concentration in patients with P. falciparum
with moderate parasitemia was signiﬁcantly higher than that in
healthy subjects (P < 0.05) and patients with fever associated
with other infections (P < 0.05). For P. vivax infection, the
concentration was signiﬁcantly higher than that in healthy sub-
jects (P < 0.05) and patients with fever associated with other
infections (P < 0.05).
3.4. Association between urinary creatinine
concentrations in urine samples and malaria infections
Median (range) values of urinary creatinine concentrations in
samples collected from all groups are summarized in Table 1.
The concentration in patients with P. falciparum with moderate
parasitemia was signiﬁcantly higher than healthy subjects
(P < 0.05) and patients with fever associated with other in-
fections (P < 0.05). For P. vivax infection, the concentration was
signiﬁcantly higher than healthy subjects (P < 0.05) and patients
with fever associated with other infections (P < 0.05).4. Discussion
PGD2 is markedly produced in the human brain to control
sleep and pain responses. PGD2 is also synthesized in mast cells
and leukocytes by a cellular, myeloid-type, glutathione-depen-
dent PGD2 synthase [7]. PfPGD2 is a potential factor derived
from intra-erythrocyte falciparum parasites. In a previous
study in human astrocyte cell line (CCF-STTG1), PGD2
increased the expression of HO-1 mRNA in a dose- and time-
dependent manner. Therefore, PGD2 might be involved in the
pathogenesis of cerebral malaria through the induction of HO-1
expression in malaria patients [5]. In another study in human
retinal pigment epithelial cells (ARPE-19, D407), PGD2 was
shown to stimulate the expression of HO-1 mRNA and protein
through binding to prostaglandin D2 receptor (DP2), linking thePGD2-DP2 with heme homeostasis [8]. Study in Gambian
children with severe malaria demonstrated that (GT) (n) repeat
polymorphism in the HMOX1 promoter inﬂuenced the
magnitude of HO-1 gene expression, while high HO-1 level
was associated with severe disease [4]. The present study aimed
to investigate the possible link between PGD2 concentrations in
plasma and urinary samples and malaria infections, through the
induction of HO-1 enzyme. Plasma PGD2 concentration was
shown to be signiﬁcantly higher in patients with P. falciparum
infection with moderate and high parasitemia compared with
healthy subjects. It was noted however that, PGD2 concentra-
tions in patients with P. vivax infection and those with fever
associated with other infections were respectively, about 2- and
4-fold of that in healthy subjects. The variability of the PGD2
concentrations measured could be due to interference from other
substances in plasma samples particularly bilirubin. Signiﬁcantly
higher serum total and direct bilirubin concentrations were
observed in samples collected from malaria patients compared
with healthy subjects. Moreover, PGD2-EIA anti-serum derived
from human PGD2 used in the EIA method might be non-
speciﬁc to PfPGD2. This may suggest the difference between
human PGD2 and PfPGD2 [9].
The possible association between PGD2 and malaria in-
fections is clearly demonstrated with PGD2 concentration in
urine. The urinary PGD2 concentrations were relatively high
(about 5-fold) in patients with P. falciparum with moderate
parasitemia and P. vivax infections compared with other groups.
Furthermore, the concentration in patients with P. falciparum
with moderate parasitemia and P. vivax infection were signiﬁ-
cantly higher than that in healthy subjects and patients with fever
associated with other infections. Urinary PGD2 concentrations
may offer a more dependable and useful tool for predicting
malaria severity. Plasma PGD2 is not a suitable matrix due to
rapid degradation of PGD2 in the presence of plasma protein
especially albumin, which complicates the analysis of PGD2 [10].
For determination of PGD2 in plasma as well as tissue
homogenates, samples needs to be extracted immediately after
collection to remove proteins and to stabilize PGD2.
Indomethacin was immediately added to whole blood sample
after collection to prevent ex vivo formation of eicosanoids
which have the potential to interfere with the EIA assay. For
urinary samples however, the addition of indomethacin is not
required [7]. Further study in a larger sample size should be
performed to conﬁrm the possible association between PGD2
Pimwan Thongdee et al./Asian Paciﬁc Journal of Tropical Medicine 2016; 9(9): 856–859 859levels and malaria infections including its predicting tool for
malaria disease severity. One limitation of the study is that
spot urine was used to measure the PGD2 levels. The spot
urine can be diluted or concentrated depending on patients'
urine volume and renal function.
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